Outlook Therapeutics, Inc. (OTLK)
0.4882
-0.01
(-2.36%)
USD |
NASDAQ |
Oct 16, 16:00
0.4918
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Net Income (Quarterly) : -20.32M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.32M |
| March 31, 2026 | -4.453M |
| December 31, 2025 | -23.06M |
| June 30, 2025 | -20.15M |
| March 31, 2025 | -46.36M |
| December 31, 2024 | 17.38M |
| September 30, 2024 | 5.691M |
| June 30, 2024 | 44.41M |
| March 31, 2024 | -114.29M |
| December 31, 2023 | -11.18M |
| September 30, 2023 | -12.99M |
| June 30, 2023 | -20.68M |
| March 31, 2023 | -6.654M |
| December 31, 2022 | -18.66M |
| September 30, 2022 | -14.34M |
| June 30, 2022 | -17.54M |
| March 31, 2022 | -19.70M |
| December 31, 2021 | -14.46M |
| September 30, 2021 | -13.40M |
| June 30, 2021 | -12.20M |
| March 31, 2021 | -13.11M |
| December 31, 2020 | -14.46M |
| Date | Value |
|---|---|
| September 30, 2020 | -9.922M |
| June 30, 2020 | -3.015M |
| March 31, 2020 | -5.700M |
| December 31, 2019 | -16.60M |
| September 30, 2019 | -10.10M |
| June 30, 2019 | -4.441M |
| March 31, 2019 | -10.31M |
| December 31, 2018 | -9.742M |
| September 30, 2018 | -12.49M |
| June 30, 2018 | -8.432M |
| March 31, 2018 | -7.922M |
| December 31, 2017 | -17.28M |
| September 30, 2017 | -7.555M |
| June 30, 2017 | -5.331M |
| March 31, 2017 | -8.046M |
| December 31, 2016 | -19.10M |
| September 30, 2016 | -10.60M |
| June 30, 2016 | -22.33M |
| March 31, 2016 | -3.542M |
| December 31, 2015 | -16.86M |
| December 31, 2014 | -4.907M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Valion Bio, Inc. | -7.057M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.0087M |
| Total Expenses (Quarterly) | 20.33M |
| EPS Diluted (Quarterly) | -0.1486 |
| Enterprise Value | 98.53M |
| Gross Profit Margin (Quarterly) | -254.0% |
| Profit Margin (Quarterly) | -233.6K% |
| Earnings Yield | -231.7% |
| Normalized Earnings Yield | -199.18 |